MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 527707 | Name: NSC-17102
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NSC-17102, also known as HF-0299 and NPC-01, is an insulin-like growth factor I stimulant potentially for the treatment of neuropathic pain and long-term treatment of dysmenorrhea.

Chemical Structure

NSC-17102
NSC-17102
CAS#382-44-5

Theoretical Analysis

MedKoo Cat#: 527707

Name: NSC-17102

CAS#: 382-44-5

Chemical Formula: C19H26O3

Exact Mass: 302.1882

Molecular Weight: 302.41

Elemental Analysis: C, 75.46; H, 8.67; O, 15.87

Price and Availability

Size Price Availability Quantity
10mg USD 210.00
100mg USD 530.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NSC-17102; NSC-17102; NSC-17102; HF-0299; NPC-01; HF 0299; NPC 01; HF0299; NPC01
IUPAC/Chemical Name
(8S,9S,10R,11S,13S,14S)-11-hydroxy-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
InChi Key
WSCUHXPGYUMQEX-KCZNZURUSA-N
InChi Code
InChI=1S/C19H26O3/c1-18-8-7-12(20)9-11(18)3-4-13-14-5-6-16(22)19(14,2)10-15(21)17(13)18/h9,13-15,17,21H,3-8,10H2,1-2H3/t13-,14-,15-,17+,18-,19-/m0/s1
SMILES Code
C[C@]1([C@](CC2)([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])[C@@H](O)C1)=O)C2=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor.
In vitro activity:
5–8F and NP69 cell lines were treated with 25, 50, or 100 μg/mL NPC01 for 24 or 48 h and measured using Annexin V–FITC/PI staining to investigate the possible apoptotic effect of NPC01 on NPC cells. Compared with the control group, NPC cell lines treated with NPC01 showed a significant increase in cell apoptotic population in a dose-dependent manner and 25 μg/mL which has no statistical significance when compared to the control (Data not shown) (Figure 2). These data suggested that NPC01 treatment promoted NPC cancer cell apoptosis. Reference: Evid Based Complement Alternat Med. 2018 Feb 13;2018:5291517. https://pubmed.ncbi.nlm.nih.gov/29636781/
In vivo activity:
In ovariectomized rats, 11betaOHA (11beta hydroxy-androstenedione) restored osteogenesis and increased the bone mineral density at both the metaphyseal and diaphyseal regions of the femur. Bone histomorphometric study of ovariectomized rats demonstrated that the mineral apposition rate of both cortical bone and trabecular bone was increased by treatment with 11betaOHA. In addition, 11betaOHA increased alkaline phosphatase activity in cultured osteoblastic cells (MC3T3-E1 and SaOS-2). Reference: J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):203-11. https://pubmed.ncbi.nlm.nih.gov/11162926/
Solvent mg/mL mM
Solubility
DMF 20.0 66.13
DMF:PBS (pH 7.2) (1:6) 0.1 0.46
DMSO 57.5 190.14
Ethanol 5.0 16.53
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 302.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yanwei L, Yinli Y, Pan Z. Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells. Evid Based Complement Alternat Med. 2018 Feb 13;2018:5291517. doi: 10.1155/2018/5291517. PMID: 29636781; PMCID: PMC5831941. 2. Suzuki Y, Nakagawa M, Sato F, Iichikawa Y, Mizushima Y. A primary adrenal steroid, 11beta-hydroxyandrostenedione, has an osteotropic effect and little androgenic activity. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):203-11. doi: 10.1016/s0960-0760(00)00124-2. PMID: 11162926.
In vitro protocol:
1. Yanwei L, Yinli Y, Pan Z. Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells. Evid Based Complement Alternat Med. 2018 Feb 13;2018:5291517. doi: 10.1155/2018/5291517. PMID: 29636781; PMCID: PMC5831941.
In vivo protocol:
1. Yanwei L, Yinli Y, Pan Z. Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells. Evid Based Complement Alternat Med. 2018 Feb 13;2018:5291517. doi: 10.1155/2018/5291517. PMID: 29636781; PMCID: PMC5831941. 2. Suzuki Y, Nakagawa M, Sato F, Iichikawa Y, Mizushima Y. A primary adrenal steroid, 11beta-hydroxyandrostenedione, has an osteotropic effect and little androgenic activity. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):203-11. doi: 10.1016/s0960-0760(00)00124-2. PMID: 11162926.
1: Harada T, Momoeda M. Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2016 Dec;106(7):1807-1814. doi: 10.1016/j.fertnstert.2016.08.051. PubMed PMID: 27717552.